PRTC - Ticker AI Digest

PureTech Health plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (PRTC) 1
PRTC 11:06
PureTech Health plc
PRTC's Seaport Advances 2nd Candidate Into Clinic
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
PRTC 11:01
PureTech Health plc
PRTC Launches Celea to Advance Ph3-Ready IPF Drug
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
PureTech Health plc (NasdaqPRTC, LSE: PRTC) announced the launch of **Celea Therapeutics**, a new Founded Entity dedicated to transforming the treatment of respiratory diseases. Celea’s lead program, **deupirfenidone (LYT-100)**, is a Phase 3-ready therapeutic candidate initially targeting **idiopathic pulmonary fibrosis (IPF)**, a rare and fatal lung disease. Former Teva North America CEO **Sven Dethlefs, PhD**, has been appointed to lead Celea, leveraging his extensive experience in respiratory medicine and commercialization.
Deupirfenidone, a deuterated form of pirfenidone, showed promising results in a Phase 2b trial, potentially offering better efficacy and tolerability compared to existing IPF treatments. PureTech plans to seek third-party funding to advance the program through Phase 3 and potential commercialization. The launch of Celea aligns with PureTech’s strategy of advancing differentiated programs through focused, capital-efficient structures.
IPF is characterized by irreversible lung scarring with a median survival of 2-5 years, and current treatments have limited efficacy and adherence. Deupirfenidone aims to address these limitations, with a market opportunity exceeding $5 billion globally. PureTech expects to meet with the FDA by Q3 2025 to discuss Phase 3 trial design.
Celea Therapeutics is part of PureTech’s innovative R&D model, which creates Founded Entities to advance promising medicines efficiently. PureTech has a robust portfolio of 29 therapeutic candidates, including three FDA-approved treatments, and remains committed to addressing devastating diseases.
**Key Highlights**
Celea Therapeutics launched to advance deupirfenidone for IPF and other fibrotic lung diseases.
Sven Dethlefs, PhD, appointed CEO, bringing expertise in respiratory medicine and commercialization.
Deupirfenidone shows potential for best-in-class efficacy and tolerability in Phase 2b trial.
PureTech seeks third-party funding for Phase 3 development and commercialization.
IPF market opportunity exceeds $5 billion, with deupirfenidone addressing unmet needs.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 1
PRTC 06:01
PureTech Health plc
Half-year Report
Results 2
PRTC 06:01
PureTech Health plc
Notice of Results
PRTC 16:13
PureTech Health plc
PRTC's Vedanta Announces VE202 Phase 2 Results
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
PRTC 16:31
PureTech Health plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 8
PRTC 11:06
PureTech Health plc
PRTC's Seaport Advances 2nd Candidate Into Clinic
PRTC 16:31
PureTech Health plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
PRTC 06:01
PureTech Health plc
Total Voting Rights
PRTC 06:01
PureTech Health plc
Half-year Report
PRTC 11:01
PureTech Health plc
PureTech Showcases Differentiated IPF Strategy
PRTC 06:01
PureTech Health plc
Notice of Results
PRTC 16:13
PureTech Health plc
PRTC's Vedanta Announces VE202 Phase 2 Results
PRTC 11:01
PureTech Health plc
PRTC Launches Celea to Advance Ph3-Ready IPF Drug
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
PureTech Health plc (NasdaqPRTC, LSE: PRTC) announced the launch of **Celea Therapeutics**, a new Founded Entity dedicated to transforming the treatment of respiratory diseases. Celea’s lead program, **deupirfenidone (LYT-100)**, is a Phase 3-ready therapeutic candidate initially targeting **idiopathic pulmonary fibrosis (IPF)**, a rare and fatal lung disease. Former Teva North America CEO **Sven Dethlefs, PhD**, has been appointed to lead Celea, leveraging his extensive experience in respiratory medicine and commercialization.
Deupirfenidone, a deuterated form of pirfenidone, showed promising results in a Phase 2b trial, potentially offering better efficacy and tolerability compared to existing IPF treatments. PureTech plans to seek third-party funding to advance the program through Phase 3 and potential commercialization. The launch of Celea aligns with PureTech’s strategy of advancing differentiated programs through focused, capital-efficient structures.
IPF is characterized by irreversible lung scarring with a median survival of 2-5 years, and current treatments have limited efficacy and adherence. Deupirfenidone aims to address these limitations, with a market opportunity exceeding $5 billion globally. PureTech expects to meet with the FDA by Q3 2025 to discuss Phase 3 trial design.
Celea Therapeutics is part of PureTech’s innovative R&D model, which creates Founded Entities to advance promising medicines efficiently. PureTech has a robust portfolio of 29 therapeutic candidates, including three FDA-approved treatments, and remains committed to addressing devastating diseases.
**Key Highlights**
Celea Therapeutics launched to advance deupirfenidone for IPF and other fibrotic lung diseases.
Sven Dethlefs, PhD, appointed CEO, bringing expertise in respiratory medicine and commercialization.
Deupirfenidone shows potential for best-in-class efficacy and tolerability in Phase 2b trial.
PureTech seeks third-party funding for Phase 3 development and commercialization.
IPF market opportunity exceeds $5 billion, with deupirfenidone addressing unmet needs.

AI Crunch

Single-Ticker AI Crunch
PRTC signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for PureTech Health plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full PRTC AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for PRTC on 2025-09-11.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
319851488
Enterprise Value
398663839
Public Float
68.76
Broker Target
501.801
Shares Out
243418190
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BY2Z0H74
Market
LSE - MAIN MARKET
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2025-08-28
Net Debt
-121498000.0
Cash
280641000.0
EPS
0.13
Net Income
53510000.0
Revenue
4315000.0
Enterprise Value
398663839
Trailing PE
10.1077
Forward PE
-
Price Sales TTM
49.5901
Price Book MRQ
1.0555
EV Revenue
15.602
EV EBITDA
2.5435

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
31.8287
Institutions As Of
2025-12-10
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
1
Sale Director Dealing
1
Purchase TR1
10
Sale TR1
7
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit PRTC.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-09-11 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
PureTech Health plc has fresh news flow feeding the chart narrative.
11:06 Today's Catalyst PRTC's Seaport Advances 2nd Candidate Into Clinic
AI Charts Studio
PRTC Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-09-11 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 15.15%
RSI Gauge
Price Change
AI Forecast